AZD5634 is an inhaled epithelial sodium channel (ENaC) inhibitor, currently being developed by AstraZeneca, that blocks the sodium channel in airway cells. By inhibiting this channel, AZD5634 may help to rehydrate the mucus that accumulates in the lungs of people with CF, making it thinner and easier to clear.1

Clinical trials involving AZD5634

AstraZeneca is preparing to start a Phase 1b study that will assess the safety, tolerability, and pharmacokinetic properties of inhaled AZD5634, as well as its effects on mucociliary clearance (MCC) in CF patients, after a single-dose administration of AD5634 (NCT02950805) compared to a single administration of a placebo. The trial, set to take place at three U.S. sites, is not yet recruiting participants.

Its primary objective is to measure the amount (in percentage) of average whole lung particle clearance up to 60 minutes following a single administration of aerosolized radiolabeled particles of AZD5634 in people with CF. Check here for the study’s contacts and locations.

A separate Phase 1 first-in-human single ascending dose study (NCT02679729) to better understand the safety, tolerability and pharmacokinetics of inhaled and intravenous AZD5634 in healthy volunteers was completed in October 2016. Its primary objectives included the frequency of adverse events up to two months after the final dose, and an assessment of changes from baseline in a wide set of health measures (including heart rate, blood rate, pulse oximetry, respiratory rate, body temperature, electrocardiogram, blood tests, physical examination, spirometry and urine evaluations).

Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



Preclinical Data Supports Effectiveness of ARO-ENaC, Arrowhead’s Investigational Therapy for CF

Preclinical data shows that Arrowhead Pharmaceuticals‘ investigational inhaled treatment for cystic fibrosis (CF), called ARO-ENaC, accelerates mucus clearance and preserves lung function while being safe for the kidneys in animal models. The data was shared recently at the 2019 North American Cystic Fibrosis Conference (NACFC) in Nashville, Tennessee. Results were presented in the poster “Therapeutic Inhibition […]

Hypertonic Saline Prolongs Mucus Clearance in Adult CF Patients, Study Finds

A single dose of inhaled hypertonic saline (HS) solution increases mucus clearance for at least four hours in adults with cystic fibrosis (CF), concludes researchers at the University of North Carolina and John Hopkins University. Their study, “Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis,” appeared in the Journal of Cystic Fibrosis. It […]

Spyryx to Present Two Studies on SPX-101’s Ability to Treat Cystic Fibrosis by Clearing Airway Mucus

Spyryx Biosciences will present two studies in Washington this week on SPX-101‘s ability to treat cystic fibrosis by clearing mucus from airways. One of the preclinical-trial studies it will discuss at the American Thoracic Society‘s annual convention showed that SPX-101 improved survival in several models of CF-like lung diseases. The event runs from May 19-24. SPX-101 mimics a […]

Mucociliary Clearance, Difficult in CF, Might Be Possible by Blocking Mucus Absorption

Blocking mucus absorption in the airways through the use of certain agents can strengthen an innate airway mechanism, called mucociliary clearance (MCC), that is often impaired in lung diseases such as cystic fibrosis (CF). The study, “Marked increases in mucociliary clearance produced by synergistic secretory agonists or inhibition of the epithelial sodium channel,” was published in the journal Scientific Reports. […]

#NACFC2016 – Getting the Upper Hand on Mucus in Cystic Fibrosis

Abnormal mucus clearance in patients with cystic fibrosis (CF) may be improved with specific treatments, but despite intense research on the subject, there are many unanswered questions about how atypical mucus contributes to the disease and how to best improve the problem. Researchers debated the issue in three discussions at a symposium titled “Mucociliary Transport and […]

#NACFC2016 – Results of Spyryx’s Investigational CF Therapy to Be Presented

Results of the safety, stability, and effectiveness of Spyryx Biosciences‘ drug candidate SPX-101 for cystic fibrosis (CF) will be presented at the North American Cystic Fibrosis Conference (NACFC) Thursday through Saturday in Orlando, Florida. SPX-101 mimics the function of the protein SPLUNC1, which plays an important role in controlling airway surface hydration and mucus clearance, a mechanism […]